Skip to main content
Top
Published in: Hereditary Cancer in Clinical Practice 1/2017

Open Access 01-12-2017 | Research

Preoperative genetic testing impacts surgical decision making in BRCA mutation carriers with breast cancer: a retrospective cohort analysis

Authors: Siddhartha Yadav, Ashley Reeves, Sarah Campian, Amy Sufka, Dana Zakalik

Published in: Hereditary Cancer in Clinical Practice | Issue 1/2017

Login to get access

Abstract

Background

The impact of timing of genetic testing on surgical decision making in women with breast cancer and BRCA mutation is not well known.

Methods

Women who were found to carry a deleterious BRCA mutation and had been diagnosed with breast cancer were identified from a database at Beaumont Health. Women who had received BRCA positive results at least a day prior to their index surgery were considered to be aware of their mutation status prior to surgery. Baseline characteristics and surgical choices were compared between women who were aware of their mutation status prior to surgery and those who were not. Fischer’s exact test was used for categorical variables and Mann–Whitney U-Test was used for continuous variables.

Results

A total of 220 patients were included in the final analysis, 208 (94.5%) with unilateral breast cancer and 12 (5.5%) with bilateral breast cancer. Out of the 208 patients with unilateral breast cancer, 106 (51.0%) patients were aware of their mutation status prior to index surgery while 102 (49%) were not. A significantly (p < 0.05) higher proportion of women underwent contralateral prophylactic mastectomy in the group that was aware of their mutation status prior to index surgery compared to the group that was not (76.4% vs 14.7%).

Conclusions

Our study demonstrates that knowledge of BRCA mutation status impacts surgical decision making in favor of bilateral mastectomy in patients who are aware of their results prior to index surgery. This finding supports the practice of preoperative genetic testing in patients with newly diagnosed breast cancer.
Literature
2.
go back to reference Peto J, Collins N, Barfoot R, et al. Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer. J Natl Cancer Inst. 1999;91:943–9.CrossRefPubMed Peto J, Collins N, Barfoot R, et al. Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer. J Natl Cancer Inst. 1999;91:943–9.CrossRefPubMed
3.
go back to reference Tung N, Lin NU, Kidd J, et al. Frequency of germline mutations in 25 cancer susceptibility genes in a sequential series of patients with breast cancer. J Clin Oncol. 2016;34:1460–8.CrossRefPubMedPubMedCentral Tung N, Lin NU, Kidd J, et al. Frequency of germline mutations in 25 cancer susceptibility genes in a sequential series of patients with breast cancer. J Clin Oncol. 2016;34:1460–8.CrossRefPubMedPubMedCentral
5.
go back to reference Haffty BG, Harrold E, Khan AJ, et al. Outcome of conservatively managed early-onset breast cancer by BRCA1/2 status. Lancet. 2002;359:1471–7.CrossRefPubMed Haffty BG, Harrold E, Khan AJ, et al. Outcome of conservatively managed early-onset breast cancer by BRCA1/2 status. Lancet. 2002;359:1471–7.CrossRefPubMed
6.
go back to reference Seynaeve C, Verhoog LC, van de Bosch LM, et al. Ipsilateral breast tumour recurrence in hereditary breast cancer following breast-conserving therapy. Eur J Cancer. 2004;40:1150–8.CrossRefPubMed Seynaeve C, Verhoog LC, van de Bosch LM, et al. Ipsilateral breast tumour recurrence in hereditary breast cancer following breast-conserving therapy. Eur J Cancer. 2004;40:1150–8.CrossRefPubMed
7.
go back to reference Basu NN, Ingham S, Hodson J, et al. Risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a 30-year semi-prospective analysis. Familial Cancer. 2015;14:531–8.CrossRefPubMed Basu NN, Ingham S, Hodson J, et al. Risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a 30-year semi-prospective analysis. Familial Cancer. 2015;14:531–8.CrossRefPubMed
8.
go back to reference Metcalfe K, Lynch HT, Ghadirian P, et al. Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. J Clin Oncol. 2004;22:2328–35.CrossRefPubMed Metcalfe K, Lynch HT, Ghadirian P, et al. Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. J Clin Oncol. 2004;22:2328–35.CrossRefPubMed
9.
go back to reference Kaas R, Verhoef S, Wesseling J, et al. Prophylactic mastectomy in BRCA1 and BRCA2 mutation carriers: very low risk for subsequent breast cancer. Ann Surg. 2010;251:488–92.CrossRefPubMed Kaas R, Verhoef S, Wesseling J, et al. Prophylactic mastectomy in BRCA1 and BRCA2 mutation carriers: very low risk for subsequent breast cancer. Ann Surg. 2010;251:488–92.CrossRefPubMed
10.
go back to reference Van Sprundel TC, Schmidt MK, Rookus MA, et al. Risk reduction of contralateral breast cancer and survival after contralateral prophylactic mastectomy in BRCA1 or BRCA2 mutation carriers. Br J Cancer. 2005;93:287–92.CrossRefPubMedPubMedCentral Van Sprundel TC, Schmidt MK, Rookus MA, et al. Risk reduction of contralateral breast cancer and survival after contralateral prophylactic mastectomy in BRCA1 or BRCA2 mutation carriers. Br J Cancer. 2005;93:287–92.CrossRefPubMedPubMedCentral
11.
go back to reference Hartmann LC, Sellers TA, Schaid DJ, et al. Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers. J Natl Cancer Inst. 2001;93:1633–7.CrossRefPubMed Hartmann LC, Sellers TA, Schaid DJ, et al. Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers. J Natl Cancer Inst. 2001;93:1633–7.CrossRefPubMed
12.
go back to reference Heemskerk-Gerritsen BA, Rookus MA, Aalfs CM, et al. Improved overall survival after contralateral risk-reducing mastectomy in BRCA1/2 mutation carriers with a history of unilateral breast cancer: a prospective analysis. Int J Cancer. 2015;136:668–77.PubMed Heemskerk-Gerritsen BA, Rookus MA, Aalfs CM, et al. Improved overall survival after contralateral risk-reducing mastectomy in BRCA1/2 mutation carriers with a history of unilateral breast cancer: a prospective analysis. Int J Cancer. 2015;136:668–77.PubMed
13.
go back to reference Metcalfe K, Gershman S, Ghadirian P, et al. Contralateral mastectomy and survival after breast cancer in carriers of BRCA1 and BRCA2 mutations: retrospective analysis. BMJ. 2014;348:g226.CrossRefPubMedPubMedCentral Metcalfe K, Gershman S, Ghadirian P, et al. Contralateral mastectomy and survival after breast cancer in carriers of BRCA1 and BRCA2 mutations: retrospective analysis. BMJ. 2014;348:g226.CrossRefPubMedPubMedCentral
14.
go back to reference Weitzel JN, McCaffrey SM, Nedelcu R, et al. Effect of genetic cancer risk assessment on surgical decisions at breast cancer diagnosis. Arch Surg. 2003;138:1323–8.CrossRefPubMed Weitzel JN, McCaffrey SM, Nedelcu R, et al. Effect of genetic cancer risk assessment on surgical decisions at breast cancer diagnosis. Arch Surg. 2003;138:1323–8.CrossRefPubMed
15.
go back to reference Schwartz MD, Lerman C, Brogan B, et al. Impact of BRCA1/BRCA2 counseling and testing on newly diagnosed breast cancer patients. J Clin Oncol. 2004;22:1823–9.CrossRefPubMed Schwartz MD, Lerman C, Brogan B, et al. Impact of BRCA1/BRCA2 counseling and testing on newly diagnosed breast cancer patients. J Clin Oncol. 2004;22:1823–9.CrossRefPubMed
16.
go back to reference Evans DG, Lalloo F, Hopwood P, et al. Surgical decisions made by 158 women with hereditary breast cancer aged <50 years. Eur J Surg Oncol. 2005;31:1112–8.CrossRefPubMed Evans DG, Lalloo F, Hopwood P, et al. Surgical decisions made by 158 women with hereditary breast cancer aged <50 years. Eur J Surg Oncol. 2005;31:1112–8.CrossRefPubMed
17.
go back to reference Yi M, Hunt KK, Arun BK, et al. Factors affecting the decision of breast cancer patients to undergo contralateral prophylactic mastectomy. Cancer Prev Res (Phila). 2010;3:1026–34.CrossRef Yi M, Hunt KK, Arun BK, et al. Factors affecting the decision of breast cancer patients to undergo contralateral prophylactic mastectomy. Cancer Prev Res (Phila). 2010;3:1026–34.CrossRef
18.
go back to reference Lokich E, Stuckey A, Raker C, et al. Preoperative genetic testing affects surgical decision making in breast cancer patients. Gynecol Oncol. 2014;134:326–30.CrossRefPubMed Lokich E, Stuckey A, Raker C, et al. Preoperative genetic testing affects surgical decision making in breast cancer patients. Gynecol Oncol. 2014;134:326–30.CrossRefPubMed
19.
go back to reference Chiba A, Hoskin TL, Hallberg EJ, et al. Impact that timing of genetic mutation diagnosis has on surgical decision making and outcome for BRCA1/BRCA2 mutation carriers with breast cancer. Ann Surg Oncol. 2016;23:3232–8.CrossRefPubMed Chiba A, Hoskin TL, Hallberg EJ, et al. Impact that timing of genetic mutation diagnosis has on surgical decision making and outcome for BRCA1/BRCA2 mutation carriers with breast cancer. Ann Surg Oncol. 2016;23:3232–8.CrossRefPubMed
21.
go back to reference Giuliano AE, Boolbol S, Degnim A, et al. Society of surgical oncology: position statement on prophylactic mastectomy. Approved by the society of surgical oncology executive council, march 2007. Ann Surg Oncol. 2007;14:2425–7.CrossRefPubMed Giuliano AE, Boolbol S, Degnim A, et al. Society of surgical oncology: position statement on prophylactic mastectomy. Approved by the society of surgical oncology executive council, march 2007. Ann Surg Oncol. 2007;14:2425–7.CrossRefPubMed
22.
go back to reference Balmana J, Diez O, Rubio IT, et al. BRCA in breast cancer: ESMO clinical practice guidelines. Ann Oncol. 2011;22:vi31–4.CrossRefPubMed Balmana J, Diez O, Rubio IT, et al. BRCA in breast cancer: ESMO clinical practice guidelines. Ann Oncol. 2011;22:vi31–4.CrossRefPubMed
23.
go back to reference Gradishar WJ, Anderson BO, Balassanian R, et al. Invasive breast cancer version 1.2016, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw. 2016;14:324–54.CrossRef Gradishar WJ, Anderson BO, Balassanian R, et al. Invasive breast cancer version 1.2016, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw. 2016;14:324–54.CrossRef
24.
go back to reference Reavey P, McCarthy CM. Update on breast reconstruction in breast cancer. Curr Opin Obstet Gynecol. 2008;20:61–7.CrossRefPubMed Reavey P, McCarthy CM. Update on breast reconstruction in breast cancer. Curr Opin Obstet Gynecol. 2008;20:61–7.CrossRefPubMed
25.
go back to reference Ropka ME, Wenzel J, Phillips EK, et al. Uptake rates for breast cancer genetic testing: a systematic review. Cancer Epidemiol Biomark Prev. 2006;15:840–55.CrossRef Ropka ME, Wenzel J, Phillips EK, et al. Uptake rates for breast cancer genetic testing: a systematic review. Cancer Epidemiol Biomark Prev. 2006;15:840–55.CrossRef
26.
go back to reference Kurian AW, Griffith KA, Hamilton AS, et al. Genetic testing and counseling among patients with newly diagnosed breast cancer. JAMA. 2017;317:531–4.CrossRefPubMed Kurian AW, Griffith KA, Hamilton AS, et al. Genetic testing and counseling among patients with newly diagnosed breast cancer. JAMA. 2017;317:531–4.CrossRefPubMed
27.
go back to reference Schwartz MD, Lerman C, Brogan B, et al. Utilization of BRCA1/BRCA2 mutation testing in newly diagnosed breast cancer patients. Cancer Epidemiol Biomark Prev. 2005;14:1003–7.CrossRef Schwartz MD, Lerman C, Brogan B, et al. Utilization of BRCA1/BRCA2 mutation testing in newly diagnosed breast cancer patients. Cancer Epidemiol Biomark Prev. 2005;14:1003–7.CrossRef
28.
go back to reference Augestad MT, Høberg-Vetti H, Bjorvatn C, et al. Identifying needs: a qualitative study of women's experiences regarding rapid genetic testing for hereditary breast and ovarian cancer in the DNA BONus study. J Genet Couns. 2017;26:182–9.CrossRefPubMed Augestad MT, Høberg-Vetti H, Bjorvatn C, et al. Identifying needs: a qualitative study of women's experiences regarding rapid genetic testing for hereditary breast and ovarian cancer in the DNA BONus study. J Genet Couns. 2017;26:182–9.CrossRefPubMed
29.
go back to reference Wevers MR, Ausems MG, Verhoef S, et al. Does rapid genetic counseling and testing in newly diagnosed breast cancer patients cause additional psychosocial distress? Results from a randomized clinical trial. Genet Med. 2016;18:137–44.CrossRefPubMed Wevers MR, Ausems MG, Verhoef S, et al. Does rapid genetic counseling and testing in newly diagnosed breast cancer patients cause additional psychosocial distress? Results from a randomized clinical trial. Genet Med. 2016;18:137–44.CrossRefPubMed
30.
go back to reference Wevers MR, Hahn DE, Verhoef S, et al. Breast cancer genetic counseling after diagnosis but before treatment: a pilot study on treatment consequences and psychological impact. Patient Educ Couns. 2012;89:89–95.CrossRefPubMed Wevers MR, Hahn DE, Verhoef S, et al. Breast cancer genetic counseling after diagnosis but before treatment: a pilot study on treatment consequences and psychological impact. Patient Educ Couns. 2012;89:89–95.CrossRefPubMed
31.
go back to reference Wevers MR, Aaronson NK, Verhoef S, et al. Impact of rapid genetic counselling and testing on the decision to undergo immediate or delayed prophylactic mastectomy in newly diagnosed breast cancer patients: findings from a randomised controlled trial. Br J Cancer. 2014;110:1081–7.CrossRefPubMedPubMedCentral Wevers MR, Aaronson NK, Verhoef S, et al. Impact of rapid genetic counselling and testing on the decision to undergo immediate or delayed prophylactic mastectomy in newly diagnosed breast cancer patients: findings from a randomised controlled trial. Br J Cancer. 2014;110:1081–7.CrossRefPubMedPubMedCentral
32.
go back to reference Cortesi L, Razzaboni E, Toss A, et al. A rapid genetic counselling and testing in newly diagnosed breast cancer is associated with high rate of risk-reducing mastectomy in BRCA1/2-positive Italian women. Ann Oncol. 2014;25:57–63.CrossRefPubMed Cortesi L, Razzaboni E, Toss A, et al. A rapid genetic counselling and testing in newly diagnosed breast cancer is associated with high rate of risk-reducing mastectomy in BRCA1/2-positive Italian women. Ann Oncol. 2014;25:57–63.CrossRefPubMed
33.
go back to reference Stanton AL, Danoff-Burg S, Huggins ME. The first year after breast cancer diagnosis: hope and coping strategies as predictors of adjustment. Psychooncology. 2002;11:93–102.CrossRefPubMed Stanton AL, Danoff-Burg S, Huggins ME. The first year after breast cancer diagnosis: hope and coping strategies as predictors of adjustment. Psychooncology. 2002;11:93–102.CrossRefPubMed
34.
go back to reference Padmanabhan N, Subramanyan A, Radhakrishna S. Synchronous bilateral breast cancers. J Clin Diagn Res. 2015;9(9):XC05–8.PubMedPubMedCentral Padmanabhan N, Subramanyan A, Radhakrishna S. Synchronous bilateral breast cancers. J Clin Diagn Res. 2015;9(9):XC05–8.PubMedPubMedCentral
35.
go back to reference Billar JA, Dueck AC, Stucky CC, et al. Triple-negative breast cancers: unique clinical presentations and outcomes. Ann Surg Oncol. 2010;17(Suppl 3):384–90.CrossRefPubMed Billar JA, Dueck AC, Stucky CC, et al. Triple-negative breast cancers: unique clinical presentations and outcomes. Ann Surg Oncol. 2010;17(Suppl 3):384–90.CrossRefPubMed
36.
go back to reference Parker PA, Peterson SK, Bedrosian I, et al. Prospective study of surgical decision-making processes for contralateral prophylactic mastectomy in women with breast cancer. Ann Surg. 2016;263:178–83.CrossRefPubMedPubMedCentral Parker PA, Peterson SK, Bedrosian I, et al. Prospective study of surgical decision-making processes for contralateral prophylactic mastectomy in women with breast cancer. Ann Surg. 2016;263:178–83.CrossRefPubMedPubMedCentral
37.
go back to reference Jones NB, Wilson J, Kotur L, et al. Contralateral prophylactic mastectomy for unilateral breast cancer: an increasing trend at a single institution. Ann Surg Oncol. 2009;16:2691–6.CrossRefPubMed Jones NB, Wilson J, Kotur L, et al. Contralateral prophylactic mastectomy for unilateral breast cancer: an increasing trend at a single institution. Ann Surg Oncol. 2009;16:2691–6.CrossRefPubMed
38.
go back to reference Sorbero ME, Dick AW, Beckjord EB, et al. Diagnostic breast magnetic resonance imaging and contralateral prophylactic mastectomy. Ann Surg Oncol. 2009;16:1597–605.CrossRefPubMed Sorbero ME, Dick AW, Beckjord EB, et al. Diagnostic breast magnetic resonance imaging and contralateral prophylactic mastectomy. Ann Surg Oncol. 2009;16:1597–605.CrossRefPubMed
39.
go back to reference Arrington AK, Jarosek SL, Virnig BA, et al. Patient and surgeon characteristics associated with increased use of contralateral prophylactic mastectomy in patients with breast cancer. Ann Surg Oncol. 2009;16(10):2697–704.CrossRefPubMed Arrington AK, Jarosek SL, Virnig BA, et al. Patient and surgeon characteristics associated with increased use of contralateral prophylactic mastectomy in patients with breast cancer. Ann Surg Oncol. 2009;16(10):2697–704.CrossRefPubMed
Metadata
Title
Preoperative genetic testing impacts surgical decision making in BRCA mutation carriers with breast cancer: a retrospective cohort analysis
Authors
Siddhartha Yadav
Ashley Reeves
Sarah Campian
Amy Sufka
Dana Zakalik
Publication date
01-12-2017
Publisher
BioMed Central
Published in
Hereditary Cancer in Clinical Practice / Issue 1/2017
Electronic ISSN: 1897-4287
DOI
https://doi.org/10.1186/s13053-017-0071-z

Other articles of this Issue 1/2017

Hereditary Cancer in Clinical Practice 1/2017 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine